focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.175%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 64.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Technology Enhancements

18 Jul 2018 07:00

RNS Number : 9050U
NetScientific PLC
18 July 2018
 

 

 

NetScientific plc

("NetScientific" or the "Company" or the "Group")

 

Portfolio Company, Wanda Enhances Remote Patient Monitoring Platform with Improved Patient Adherence Features

 

London, UK - July 18th, 2018 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that portfolio company Wanda, which uses machine learning to help healthcare providers to better manage the risk and care of patients, has completed a significant enhancement of its Patient Management Platform to improve patient adherence to care plans. Use of Wanda's existing platform had been shown to predict 90% of patient-level adverse events up to 7 days in advance of their occurrence, and allows for virtual intervention to prevent such events.

 

The new enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalised reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech Application Programming Interface from Google that uses machine learning to deliver natural-sounding human voice automation. The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence.

 

Commenting on the news, Francois R. Martelet, NetScientific's Chief Executive Officer and Chairman of Wanda, said: "Wanda's enhancements to its core technology mean that relationships between clinicians and patients will continue to improve, and will empower patients to take a more active role in the management of their diseases as well as increase their quality of life. We continue to see invaluable potential in Wanda and look forward to monitoring its progress in the coming months."

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Wanda, Inc.

Bill Basset, CCO

Tel: +1 (0)206 910 0428

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Wanda Expands Patient Management Platform with Enhanced Patient Adherence Features

San Francisco, CA - July 18th, 2018 - Wanda, Inc. announces a significant expansion of their market-leading Patient Management Platform with expansive new features to further improve patient care plan adherence. The Wanda solution, embedded with clinically proven machine learning, predicts 90% of patient-level adverse events seven days before they occur and then facilitates virtual interventions to keep them from occurring. The enhanced Patient Reminder Suite empowers clinicians to better engage patients in care plan adherence through personalized reminders and alerts, which can be pre-scheduled and delivered via multi-modal communications. The enhancements also include the adoption of the Cloud Text-to-Speech API from Google that uses machine learning to deliver natural-sounding human voice automation.

The combined effect of the enhanced reminder tools, the early prediction of adverse events, and the virtual intervention insight gives providers a highly intelligent method to defend against the costs of unplanned readmissions and emergency department visits due to nonadherence. Depending on the complexity of the care plan, as many as 40% of patients fail to adhere to treatment plans.1 Between $100 and $300 billion in avoidable health care costs have been attributed to non-adherence in the US annually, representing 3%-10% of total US healthcare costs.2

"Healthcare providers have been pleased with how the Wanda platform has positively impacted the relationship between patients and their clinical care teams. The clinicians are able better deliver on their mission to provide great care with meaning and timely insight. Patients are more engaged and in control of the care", stated William Bassett, Chief Commercialization Officer of Wanda, Inc.

A key driver in patient non-adherence is related to medications with adherence rates dropping to 20% for patients that are required to take thirteen or more medications per day.3 Patient non-adherence can be corrected by the patient with the appropriate support. The leading reason for non-adherence most commonly reported was forgetfulness by the patient.4 The Patient Reminder Suite in Wands is specifically designed help clinicians easily create, personalize, and schedule reminders for all types of care support needs including medication reminders, vitals, daily symptom survey questions, pending visits to the doctor or at home visits, and prompts to exercise. For patients that prefer to interact with Wanda using the interactive voice response model, the inclusion of the Google voice technology provides a warm sounding human voice adding even more satisfaction to the patient interaction.

"Wanda continues to expand on its mission to fuse cutting edge data science with clinical care management to solve the major roadblocks in care models," said Ahsan Samiee, Chief Technology Officer, Wanda, Inc. "The financial and clinical results achieved by customers continue to validate our belief that these approaches should be imbued across healthcare for the betterment of all."

 

1, 3. Martin L, Williams S, Haskard, DiMatteo M. 2005. The Challenge of Patient Adherence. Therapeutics and Clinical Risk Management. 2005; 189-199.

2, 4. Iuga A, McGuire M. 2014. Adherence and Health Care Costs. Risk Management and Healthcare Policy. 2104; 35-44.

 

About Wanda, Inc.

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRABBGDRRGBBGIR
Date   Source Headline
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.